PARIS — Adding the PCSK9 inhibitor evolocumab (Repatha, Amgen) to high-intensity statin therapy in the very high-risk setting of acute coronary syndrome (ACS) safely lowers low-density lipoprotein ...
The European Society of Cardiology (ESC) Guidelines on acute coronary syndromes are published online today in European Heart Journal. The document covers the management of unstable angina and all ...
Anna Mueller, MD, and Amir Ahmadi, MD, of Mount Sinai, highlight gaps in risk assessment tools for acute coronary syndrome, calling for more comprehensive screening strategies. New data from a poster ...
Two posters presented at the CHEST 2024 annual meeting highlighted significant disparities in acute coronary syndrome care and outcomes among different racial, ethnic, and gender groups, underscoring ...
In patients with an acute coronary syndrome who undergo coronary-artery revascularization with stent implantation, dual antiplatelet therapy with aspirin and a P2Y12 inhibitor (e.g., clopidogrel, ...
People have the right to be involved in discussions and make informed decisions about their care, as described in NICE's information on making decisions about your care. Making decisions using NICE ...
Coronary artery disease (CAD) is the leading cause of death worldwide, with acute myocardial infarction (MI) representing the ...
Early-Onset AKI Tied to Poor Prognosis in Cardiogenic Shock Acute kidney injury occurring within 48 hours of infarct-related cardiogenic shock marks a high-risk haemodynamic phenotype with higher ...
Introduction Poor adherence to risk factor control and life-saving medications is a key factor affecting long-term patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results